Precigen Receives FDA Orphan Drug Designation for PRGN-2012 AdenoVerse™ Immunotherapy in Patients with Recurrent Respiratory Papillomatosis (RRP)

/PRNewswire/ -- Precigen, Inc., a biopharmaceutical company specializing in the development of innovative gene and cell